The findings led to an early halt of a small study comparing Niaspan and Zetia, two compounds commonly used along with statins to reduce heart attack risk ORLANDO, Fla. — Adding a pharmaceutical form of the B vitamin niacin — but not the drug ezetimibe — to a cholesterol-lowering statin drug appears to reduce artery plaque buildup in patients with coronary artery disease, according to much-anticipated results announced at a press conference November 15. The results were from a study that was relatively small — only 208 patients — but provided a head-to-head comparison of niacin and ezetimibe, known by...